预约演示

Surrozen's Wnt mimetic antibody improves lung function in mice with pulmonary fibrosis

2024-04-04

临床1期

In mice with idiopathic pulmonary fibrosis, twice-weekly injections of Surrozen's molecule for two and a half weeks decreased lung fibrosis, reduced inflammation and improved lung function compared to controls.

A Wnt/β-catenidiopathic pulmonary fibrosislopment by Surrozen appears to be effective against idiopathic pulmonary fibrosis (Ilung fibrosismodels, acinflammationew data.

ThWnt/β-catenin pathway agonistin the journal Respiratory Research, are an early signal of a pidiopathic pulmonary fibrosis (IPF)pany’s SWAP technology.

“Current treatments for severe lung disease like IPF aren’t able to regenerate normal, functional tissue,” Yang Li, Ph.D., executive vice president of research at Surrozen, said in a press release. “This work … represents a breakthrough in understanding the role of the Wnt pathway in lung fibrosis and the potential for Wnt mimetics to reduce fibrosis and improve lung function.”

IPF is a condition where scar tlung disease up inIPFe lungs, making it difficult to breathe. It occurs in about 13 to 20 in every 100,000 people globally, most of Surrozenween the ages of 50 and 70. IPF is sporadic and doesn’t have a clear cause, though there are a handful of linked glung fibrosis and known risk factorsWnt mimetics include smfibrosisxposure to wood or metal dust and some drugs such as certain antibiotics, heart medications and cancer therapies.

IPF Wnt/B-catenin signaling pathway is a group of proteins that are heavily involved in tissue development and maintenance, including in the lungs. Prior to the new study, it wasn’t clear whether actIPFting the pathway was helpful or harmful in IPF, as there was some evidence that genes associated with its activation were elevated in patient tissue samples and mouse models, the researchers noted in the article.cancer

On tWntoB-catenin, a type of stem cell found in the lungs requires Wnt signaling activity for cell maintenance and renewal, and research in mice suggested that activating the pathway decreases lung inflammation.IPF

After demonstrating in mice that activating the pathway was more beWnticial against IPF than suppressing it, Surrozen researchers tested out a molecule called a Wnt mimetic antibody, which mirrlung inflammationf proteins involved in Wnt pathway signaling. In mice with IPF, twice-weekly injections of the molecule for two and a half weeks decreased lung fibrosis, reduced inflammation and improved lung function compared to controls. The antibody's benefits appeared to come from its activity on several different types of cells, including cells of the alveoli—the tiny air sacs in the lungs—as well as stromal and immune cells.

“Our findings suggest there is great potential for modulating Wnt/B-catenin signalinIPFo treat lung diseases including IPF—a possibility warranting more thoroughWnt mimetic antibodyesearchers wrote in the article. They plan to continWnt pathwayop Wnt mimics that targetIPFecific cell types, which would enable therapies with a lower risk of systemiclung fibrosis.inflammation

Surrozen’s focus on the Wnt pathway has yielded two candidatesWnt B-catenin043 for alcohol-assolung diseasestis and SZNIPF3 for retinal disease. The company had also been developing another drug, SZN-1326, for inflammatory bowel disease but halted that program in January due to side effects.

Surrozenis currently being tested in a phase 1b trial, for which the coSZN-043ay haalcohol-associated hepatitisf 202SZN-413SNZ-4retinal diseaseing co-developed with Boehringer Ingelheim, the bioteSZN-1326nced Ainflammatory bowel diseaseed a phase 1a trial and was in the process of initiating phase 1b.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构